IART
Integra LifeSciences Holdings Corporation
IART trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over IART overall, supported by stronger valuation and stronger modeled upside.
IART Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
IART's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IART PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.2x | $14.35 | — |
| Cheap | 26x | $4.14 | -71% |
| Fair | 34x | $5.42 | -62% |
| Expensive | 84x | $13.36 | -6.9% |
| Current | 90x | $14.35 | — |
Historical ranges are pointers, not guarantees.
IART's PE is in its expensive range at 90x. On analysts' estimates for next year's earnings, today's price would be 6.2x, in its cheap range.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over IART in the historical PE scenario, which offers more potential upside but is not a forecast.
IART Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect IART's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over IART on the outlook, with more favorable earnings and revenue expectations.
IART Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +1357% |
| Q3 2026 | $0.16 | +$6.62 |
| Q2 2026 | -$0.10 | +$6.43 |
| Q1 2026 | -$6.47 | -$6.09 |
| Q4 2025 | -$6.74 | -$6.65 |
| Q3 2025 | -$6.46 | -$6.38 |
| Q2 2025 | -$6.53 | -2277% |
| Q1 2025 | -$0.38 | -175% |
| Q4 2024 | -$0.09 | -111% |
IART has returned to profit: it earned $0.16 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IART on earnings, with more consistent year-over-year improvement.
IART Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $411.2M | +2.3% |
| Q2 2026 | $418.8M | +0.8% |
| Q1 2026 | $391.9M | +2.4% |
| Q4 2025 | $434.9M | -1.7% |
| Q3 2025 | $402.1M | +5.6% |
| Q2 2025 | $415.6M | -0.6% |
| Q1 2025 | $382.7M | +3.7% |
| Q4 2024 | $442.6M | +11% |
IART's revenue grew through 2021 and has held roughly level since: $411M last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.6% | +1.7 points |
| Q2 2026 | 4.6% | +128 points |
| Q1 2026 | 2.9% | +7 points |
| Q4 2025 | 5.3% | -2.8 points |
| Q3 2025 | 2.9% | +5.1 points |
| Q2 2025 | -123% | -123 points |
| Q1 2025 | -4% | -5.1 points |
| Q4 2024 | 8.1% | -1 points |
IART's operating margin was 4.6% last quarter, up 1.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IART on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IART on profitability, with a higher operating margin.
IART Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $85.7M | +233% |
| Q2 2026 | $10.5M | +$21.7M |
| Q1 2026 | -$5M | +$35.1M |
| Q4 2025 | -$5.4M | -126% |
| Q3 2025 | $25.8M | +$32.9M |
| Q2 2025 | -$11.2M | -205% |
| Q1 2025 | -$40.2M | -13907% |
| Q4 2024 | $21.1M | -38% |
IART's free cash flow has turned positive again: $86M over the past year, against −$5M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over IART on cash flow, with more consistent year-over-year improvement.
IART Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +409K shares |
| 1 year | +2.4% | +1.8M shares |
| 3 years | -1.5% | -1.2M shares |
| 5 years | -8% | -6.9M shares |
| Available history | -9.2% | -7.9M shares |
IART has 79M diluted shares, up 2.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $2.5M |
| Q3 2024 | — |
| Q2 2024 | $50M |
| Q1 2024 | — |
| Q4 2023 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IART on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IART Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 3.0x | Elevated |
| Q1 2020 | 2.6x | Moderate |
| Q4 2019 | 3.3x | Elevated |
IART's net debt is about 3.0 years of its operating earnings (EBITDA).
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IART Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 26.2 | Neutral |
IART's weekly RSI is 49 (neutral) and its Stochastic is 26 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IART PE vs Healthcare Sector
| Metric | IART | Sector median | Relative |
|---|---|---|---|
| PE | 90x | 26x | 247% above |
| PE % | 89 | 29 | 60 pts above |
IART is trading at 90x earnings, a 247% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over IART on valuation relative to its sector.
IART Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.5 | 6.5% above |
| 20 week MA | $15.9 | 9.5% below |
| 50 week MA | $13.9 | 3.2% above |
| 100 week MA | $15.3 | 6.1% below |
| 200 week MA | $26.4 | 46% below |
IART's trend is mixed: it's above two of its five weekly moving averages, and 46% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IART on trend strength, trading above more of its moving averages.
IART Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.7 | $66.4 | +13% |
| 2021 | $66.4 | $68.3 | +2.8% |
| 2022 | $68.3 | $56.3 | -18% |
| 2023 | $56.3 | $43.6 | -23% |
| 2024 | $43.6 | $22.3 | -49% |
| 2025 | $22.3 | $12.6 | -43% |
| 2026 YTD | $12.6 | $14.4 | +14% |
IART has finished four years in a row lower, and it's up 14% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IART on returns for 2026, with the stronger performance.